<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297462</url>
  </required_header>
  <id_info>
    <org_study_id>77/PB/2016</org_study_id>
    <nct_id>NCT04297462</nct_id>
  </id_info>
  <brief_title>Different Regimens in Influenza Postexposure Chemoprophylaxis in Children</brief_title>
  <official_title>Efficacy of Different Regimens in Influenza Postexposure Chemoprophylaxis With Oral Neuraminidase Inhibitor in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre of Postgraduate Medical Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre of Postgraduate Medical Education</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although the vaccination is the preferred method of influenza prevention, there are some&#xD;
      occasions on which a postexposure prophylaxis (PEP) is required. Two neuraminidase inhibitors&#xD;
      (NAIs) may be used in chemoprophylaxis in children: oral oseltamivir, and inhaled zanamivir.&#xD;
      Both, oseltamivir and zanamivir, are effective in treatment and in prophylaxis of influenza,&#xD;
      and the efficacy is calculated to reach 70-90%. Oseltamivir is used more frequently, since&#xD;
      zanamivir is licensed in older children (5 years of age and above), and children under the&#xD;
      age of 5 years are at higher risk of influenza complications. Oseltamivir use correlated in&#xD;
      children with higher risk of vomiting, with no increased risk of other adverse events,&#xD;
      including those observed in adult patients (nausea, renal events, and psychiatric effects).&#xD;
      The PEP may be indicated by individual patient's characteristics (e.g. patients in high-risk&#xD;
      group) or epidemiological reasons, i.e. prevention of institutional outbreaks.The one&#xD;
      research that analyzed efficacy of 3-days PEP versus 7 or 10-days and showed overall efficacy&#xD;
      of shorter oseltamivir prophylaxis to be high and comparable to that of longer regimens. The&#xD;
      study included several pediatric patients and made the investigators perform such an analysis&#xD;
      in pediatric population. In this randomized controlled trial, the investigators aimed to&#xD;
      compare efficacy, safety, and costs of 3 versus 7-days prophylaxis with oral oseltamivir in&#xD;
      children hospitalized. The hypothesis is that 3-days duration of PEP is not less effective&#xD;
      than 7-days PEP, and patients might gain from lower number of adverse reactions related to&#xD;
      drug administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Only applies to patients hospitalized due to other than influenza reasons. If a proven&#xD;
      contact with influenza has taken place (influenza diagnosed by signs/symptoms and positive&#xD;
      rapid influenza diagnostic test and/or PCR), a patient may be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients randomly allocated into 3 or 7-days postexposure chemoprophylaxis group</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postexposure chemoprophylaxis efficacy</measure>
    <time_frame>up to 7 days after PEP has finished</time_frame>
    <description>Percent of patients who did not have influenza in each study arm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Oseltamivir safety</measure>
    <time_frame>up to 7 days after PEP has finished</time_frame>
    <description>Presence of the following adverse reactions to drug (in percents): nausea, vomiting, skin hypersensitivity (including rash), sleep disorders, consciousness disorders, convulsions, fever related to drug administration, symptomatic arrhythmias, behavioral changes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Postexposure chemoprophylaxis costs</measure>
    <time_frame>up to 7 days after PEP has finished</time_frame>
    <description>Cost of drugs used in each arm, costs of treatment of adverse reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for hospitalization in case of influenza after failed chemoprophylaxis</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>A need for hospitalization if influenza is present within 7 days after PEP completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of influenza signs and symptoms after failed chemoprophylaxis</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Length of period when signs and symptoms are present</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of complications in case of influenza after failed chemoprophylaxis</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Presence of influenza complications: pneumonia, bronchitis, otitis media, need for antibiotic treatment, neurological sequelae, ICU transfer, death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever in case of influenza after failed chemoprophylaxis</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Highest fever and duration of fever</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Influenza</condition>
  <condition>Exposure</condition>
  <condition>Prevention</condition>
  <arm_group>
    <arm_group_label>3-days postexposure chemoprophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oseltamivir given orally, 3mg per each body kg, once a day during three consecutive days after the contact with influenza</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7-days postexposure chemoprophylaxis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oseltamivir given orally, 3mg per each body kg, once a day during seven consecutive days after the contact with influenza</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir 3 days</intervention_name>
    <description>Non-inferiority study of 3 versus 7-days duration of PEP</description>
    <arm_group_label>3-days postexposure chemoprophylaxis</arm_group_label>
    <other_name>3-days postexposure chemoprophylaxis with oseltamivir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oseltamivir 7 days</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>7-days postexposure chemoprophylaxis</arm_group_label>
    <other_name>7-days postexposure chemoprophylaxis with oseltamivir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients hospitalized at the Pediatric Ward&#xD;
&#xD;
          -  age: 0-18 years old&#xD;
&#xD;
          -  confirmed contact with a person diagnosed with influenza&#xD;
&#xD;
          -  patient's, patient's parent/tutor's informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lack of an informed consent&#xD;
&#xD;
          -  more than 48 hours after the first contact with influenza&#xD;
&#xD;
          -  severe adverse reaction to the drug- discontinuation of the prophylaxis&#xD;
&#xD;
          -  important to a parent/tutor drug intolerance (e.g. lack of tolerance of a drug's&#xD;
             taste)&#xD;
&#xD;
          -  new contact with influenza after chemoprophylaxis has finished&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>August E. Wrotek, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Centre of Postgraduate Medical Education</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>August E. Wrotek, MD, PhD</last_name>
    <phone>(+48)228641167</phone>
    <email>august.wrotek@bielanski.med.pl</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Centre of Postgraduate Medical Education</name>
      <address>
        <city>Warsaw</city>
        <state>Mazowieckie</state>
        <zip>01-813</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>August E. Wrotek, MD PhD</last_name>
      <phone>(+48)228641167</phone>
      <email>august.wrotek@bielanski.med.pl</email>
    </contact>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/?term=ishiguro+postexposure</url>
    <description>Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards.</description>
  </link>
  <reference>
    <citation>Ishiguro N, Oyamada R, Nasuhara Y, Yamada T, Miyamoto T, Imai S, Akizawa K, Fukumoto T, Iwasaki S, Iijima H, Ono K. Three-day regimen of oseltamivir for postexposure prophylaxis of influenza in wards. J Hosp Infect. 2016 Oct;94(2):150-3. doi: 10.1016/j.jhin.2016.05.012. Epub 2016 May 25.</citation>
    <PMID>27346624</PMID>
  </reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>February 18, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>September 7, 2020</last_update_submitted>
  <last_update_submitted_qc>September 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre of Postgraduate Medical Education</investigator_affiliation>
    <investigator_full_name>August Wrotek</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>influenza</keyword>
  <keyword>chemoprevention</keyword>
  <keyword>oseltamivir</keyword>
  <keyword>child</keyword>
  <keyword>infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oseltamivir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

